Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia

NCT05720988 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped trial was not opened

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Azacitidine
BIOLOGICAL: Tagraxofusp-erzs

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

[object Object]